…disease, to fluticasone furoate/vilanterol, fluticasone furoate, vilanterol or placebo (Vestbo 2016). Median study exposure was 1.8 years in this event-driven RCT. No benefit for all-cause mortality was seen with any…
…doctor-diagnosed exacerbation of COPD (McKeever 2016). A VBG pH ≤7.34 gave a sensitivity of 88.9% and specificity of 95.6% for an ABG pH ≤7.35. The authors argued that all patients…
…of eight studies of the CAT questionnaire demonstrates moderately strong predictive values for aspects of COPD including a valid diagnosis, likelihood of exacerbations, depression, lung function and mortality (Karloh 2016)….
Appendix 3 Long term oxygen therapy (McDonald 2016) Initiating oxygen therapy Before introducing oxygen therapy, ensure optimal treatment of the pulmonary disorder while monitoring improvement with objective tests such as…
…2016). A retrospective Australian study examined oxygen use in 111 patients admitted with hypercapnia due to an exacerbation of COPD. Over-oxygenation was common and was significantly more likely to occur…
…of one mode of delivery over another for bronchodilators during exacerbations of COPD. In a Cochrane Review by van Geffen (van Geffen 2016) there were no differences between nebulisers and…
…potentially pathogenic microorganisms in sputum (OR 4.1), severe airway obstruction (OR 1.3) and mortality (OR 2.0) (Du 2016). These studies emphasise the clinical importance of coexisting bronchiectasis in some patients…
…of severe exacerbations (OR 1.51, 95% CI 1.04 to 2.17), while SHS exposure in the last week was associated with worse SGRQ and more symptoms (Putcha 2016) [evidence level III-2]….
…and anticipation of increased risks associated with those comorbidities in the presence of COPD (Gershon 2016). An American population based, nationally representative survey of almost 15,000 people demonstrated that patients…
…2016). Rates of pneumonia were similar between fluticasone furoate and placebo groups (Vestbo 2016a, Crim 2017) Vestbo et al (Vestbo 2016b) performed an open label randomised trial in 75 UK…